- Common shares of Britannia Life Sciences (BLAB) have been accepted for listing on the Frankfurt Stock Exchange under the symbol L020
- Britannia Life Sciences Inc. offers an integrated suite of services to assist companies along their product development journey
- Services include product formulations, safety assessments, analytical and microbiological testing, global compliance and consumer evaluations
- Britannia Life Sciences Inc. (BLAB) opened trading at C$0.20 per share
Common shares of Britannia Life Sciences (BLAB) have been accepted for listing on the Frankfurt Stock Exchange under the symbol L020.
The listing of Britannia shares on the FSE represents the first step in the company’s strategy to improve access and awareness to global investors, in particular in the UK and Europe where the bulk of Britannia’s operations are based.
Peter Shippen, Britannia’s CEO, commented on the FSE listing.
“We are pleased to be listed on to the Frankfurt Stock Exchange and trade in Europe where many of our larger competitors command significantly higher trading multiples. As Britannia continues to build out our global product platform and expand our services in new areas, we feel it is important that UK and European investors can confidently and efficiently trade our shares and participate in Britannia’s growth.”
Britannia Life Sciences Inc. is a global platform offering an integrated suite of services to assist companies along their product development journey. Britannia’s services, which include product formulations, safety assessments, analytical and microbiological testing, global compliance and consumer evaluations are offered to companies ranging from multinationals to start-ups, particularly in the cosmetics, food and wellness industries.
Britannia Life Sciences Inc. (BLAB) opened trading at C$0.20 per share.
